Search Results

You are looking at 1 - 10 of 3,224 items :

  • "Metabolic syndrome" x
Clear All

References 1. Breitrose, PE. History (of the Stanford Prevention Research Center). [Online] Stanford Prevention Research Center. [Dátum: 1. FEB 2011.] 2. Chung, CP; Avalos, I; Oeser, A; Gebretsadik, T; Shintani, A; Raggi, P; Michael Stein, C. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis. 2007, 66, 208-214 pp. 3. Chung, CP; Oeser, A; Solus, JF; Avalos, I; Gebretsadik, T; Shintani, A

References 1. Alberti, K.G.M. & Zimmet, P. (2007). Metabolic syndrome: Nomenclature, Definition and Diagnosis. In: Krentz AJ, Wong ND (Eds). Metabolic Syndrome and Cardiovascular Disease Epidemiology, Assessment and Management (pp. 1 - 15). New York: Informal Healthcare. 2. Reaven, G.M. (2005). The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr . 25, 391-406. 3. Reaven, G.M. (1998). Role of insulin resistance in human disease. Diabetes. 37, 1595-1607. 4. Kaplan, N.M. (1989). The deadly quartet: upper-body obesity

[1] Reaven G.M., Banting lecture 1988. Role of insulin resistance in human disease, Diabetes, 1988, 37. 1595–1607 [2] Alberti K.G.M.M., Zimmet P., Shaw J., for the IDF Epidemiology Task Force Consensus Group, The metabolic syndrome-a new worldwide definition, Lancet, 2005, 366(9491), 1059–1062 [3] Zimmet P., Alberti G., Kaufman F., Tajima N., The metabolic syndrome in children and adolescents, Lancet, 2007, 369(9579), 2059–2061

(6):898-908,2016 5. Lopez DS, Advani S, Tsilidis KK, Wang R, Canfield S. Endogenous and exogenous testosterone and prostate cancer: decreased, increased or null-risk? Transl Androl Urol . 6(3): 566-579, 2017 6. Bjorntorp P . Endocrine abnormalities in obesity. Diabetes Rev 5: 52-68, 1997 7. Laaksonen DE, Niskanen L, Punnonen K et al . Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27(5):1036-1041, 2004 8. Kolovou GD, Anagnostopoulou KK, Salpea KD, Mikhailidis DP . The prevalence of metabolic

Bibliography 1. Yki-Jarvinen. H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. LancetDiabetes Endocrinol 2014; 2(11): 901–10 2. Lonardo A, Ballestri S, Marchesini G et al. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Dig LiverDis 2015; 47: 181–90. 3. Fukuda T, Hamaguchi M, Kojima T et al. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int 2016; 36: 275–83. 4. Matteoni C, Younossi Z, Gramlich T et al. Nonalcoholic fatty

R eferences 1. Samson SL, Garber AJ . Metabolic syndrome. Endocrinol Metab Clin North Am 43(1): 1-23, 2014 2. Zureik M, Kauffmann F, Touboul P, Courbon D, Ducimetiere P. Association between peak expiratory flow and the development of carotid atherosclerotic plaques. Archives of internal medicine 161(3): 1669-1676, 2001 3. McAllister DA, Newby DE . Association between Impaired Lung Function and Cardiovascular Disease. Cause, Effect, or Force of Circumstance. Am J Respir Crit Care Med 194(1): 3-5, 2016 4. Sin DD, Wu L, Man SP. The relationship between

Irodalom 1. Kucerova J, Babinska Z, Horska K, Kotolova H. The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression. A review. Biomed. Pap. Med. Fac. Univ. Palacký, Olomouc, Czechoslov. 2015;159:208–14. 2. Barnard K, Peveler RC, Holt RIG. Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation. Diabetes Care. 2013;36:3337–45. 3. Olguner Eker O, Ozsoy S, Eker B, Dogan H. Metabolic Effects of Antidepressant Treatment. Noro Psikiyatr. Ars. 2017;54:49–56. 4. Corruble E, El Asmar K, Trabado S

[1] Shaffer E.A., Gallstone disease: Epidemiology of gallbladder stone disease, Best Pract. Res. Clin. Gastroenterol., 2006, 20(6), 981–996 [2] Méndez-Sánchez N., Chavez-Tapia N.C., Motola-Kuba D., Sanchez-Lara K., Ponciano-Rodríguez G., Baptista H., Ramos M.H., Uribe M., Metabolic syndrome as a risk factor for gallstone disease, World J. Gastoenterol., 2005, 11(11), 1653–1657 [3] Grundy S.M., Cholesterol gallstones: a fellow traveler with metabolic syndrome? Am. J. Clin. Nutr., 2004, 80(1), 1–2 [4] Alberti K

References 1. Kraja AT, Vaidya D, Pankow JS, Goodarzi MO, Assimes TL, Kullo IJ, et al. A bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium. Diabetes. 2011;60:1329-39. DOI: 10.2337/db10-1011. 2. Bruce KD, Hanson MA. The developmental origins, mechanisms, and implications of metabolic syndrome. J Nutr. 2010;140(3):648-52. DOI: 10.3945/ jn.109.111179. 3. Laker RC, Wlodek ME, Connelly JJ, Yan Z. Epigenetic origins of metabolic disease: The impact of the maternal condition to the offspring epigenome and later health consequences. Food Science

References 1. Olufadi R, Byrne CD . Clinical and laboratory diagnosis of the metabolic syndrome. J Clin Pathol 61: 697-706, 2008. 2. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752, 2005. 3. Hanley AJ, Karter AJ, Williams K et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation 112: 3713